President Trump meets with representatives from PhRMA. Photo: Ron Sachs - Pool/Getty Images

The pharmaceutical industry's 2 leading trade groups both set records for lobbying spending in 2018 — a sign of just how much the industry believes is on the line in the political battle over drug prices.

By the numbers: PhRMA, the industry's largest trade organization, spent $27.5 million on lobbying last year, per Bloomberg. That's the most it has ever spent in 1 year. A full $10 million of that came in the first quarter — the most PhRMA has ever spent in a single quarter.

The Biotechnology Innovation Organization, meanwhile, spent just shy of $10 million, according to STAT — also a record.

  • Those totals don't include the millions individual drug companies spent on their own lobbyists. They also don't include the industry's campaign contributions, which topped $17 million in the 2018 cycle, according to the Center for Responsive Politics.

Between the lines: PhRMA set its previous lobbying record during the debate over the Affordable Care Act, trying to stop a fully Democratic government from taking a bite out of its bottom line.

  • It's remarkable that PhRMA would break that record in a year where Republicans — the industry's allies — controlled the House, Senate and White House.

Go deeper

Felix Salmon, author of Capital
21 mins ago - Economy & Business

A white-collar crime crackdown

Illustration: Eniola Odetunde/Axios

America has waited a decade for an aggressive government crackdown on white-collar crime. Now, just before the election, and in the middle of a bull market, it has arrived.

Why it matters: When times are good, investors become more trusting and more greedy. That makes them more likely to put their money into fraudulent or criminal enterprises.

  • After a decade-long bull market, there is no shortage of those frauds to prosecute.
48 mins ago - Technology

Lawyers crystal-ball the Google antitrust case

Illustration: Eniola Odetunde/Axios

The Justice Department's antitrust suit against Google is a strong, straightforward monopoly case, competition lawyers and experts tell Axios. But that doesn't mean it'll be an easy journey for the government.

The big picture: Winning any antitrust case is a heavy lift. It's even more of a challenge to pull off victory in a future-looking case that seeks to make room for potential new competition to flourish.

The pandemic is getting worse again

Expand chart
Data: The COVID Tracking Project, state health departments; Note: Due to a database error, Missouri had a 3 day gap in reporting from Oct. 11-13; Map: Andrew Witherspoon/Axios

Every available piece of data proves it: The coronavirus pandemic is getting worse again, all across America.

The big picture: As the death toll ticks past 212,000, at a moment when containing the virus ought to be easier and more urgent than ever, we are instead giving it a bigger foothold to grow from.